Margaret Ancona Myriad Genetics Inc (MYGN) insider trading activity

Margaret Ancona is EVP, Strategy & Transformation of MYRIAD GENETICS INC. Currently has a direct ownership of 127,726 shares of MYGN, which is worth approximately $1.03 Million. The most recent transaction as insider was on Sep 21, 2025, when has been sold 958 shares (Common Stock) at a price of $7.77 per share, resulting in proceeds of $7,443. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 128K

0.74% 3M change

62.92% 12M change

Total Value Held $1.03 Million

Margaret Ancona Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 21 2025	SELL Payment of exercise price or tax liability	$7,443 $7.77 p/Share	958 Reduced 0.74%	127,726 Common Stock
Mar 22 2025	SELL Payment of exercise price or tax liability	$26,246 $10.01 p/Share	2,622 Reduced 2.0%	128,684 Common Stock
Mar 15 2025	SELL Payment of exercise price or tax liability	$15,830 $10.07 p/Share	1,572 Reduced 1.18%	131,306 Common Stock
Mar 14 2025	SELL Payment of exercise price or tax liability	$34,409 $10.07 p/Share	3,417 Reduced 2.51%	132,878 Common Stock
Mar 13 2025	BUY Grant, award, or other acquisition	-	54,124 Added 28.42%	136,295 Common Stock
Feb 25 2025	SELL Payment of exercise price or tax liability	$31,662 $11.74 p/Share	2,697 Reduced 3.44%	75,703 Common Stock
Feb 07 2025	BUY Grant, award, or other acquisition	-	6,468 Added 7.3%	82,171 Common Stock
Sep 21 2024	SELL Payment of exercise price or tax liability	$26,700 $27.64 p/Share	966 Reduced 1.22%	78,400 Common Stock
Aug 21 2024	SELL Open market or private sale	$320,987 $27.82 p/Share	11,538 Reduced 12.69%	79,366 Common Stock
Mar 22 2024	SELL Payment of exercise price or tax liability	$16,235 $22.24 p/Share	730 Reduced 0.8%	90,904 Common Stock
Mar 15 2024	SELL Payment of exercise price or tax liability	$33,538 $21.16 p/Share	1,585 Reduced 1.7%	91,634 Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	35,178 Added 27.4%	93,219 Common Stock
Feb 25 2024	SELL Payment of exercise price or tax liability	$50,688 $22.72 p/Share	2,231 Reduced 3.7%	58,041 Common Stock
Sep 21 2023	BUY Grant, award, or other acquisition	-	10,000 Added 14.23%	60,272 Common Stock
Mar 22 2023	SELL Payment of exercise price or tax liability	$17,205 $22.91 p/Share	751 Reduced 1.47%	50,272 Common Stock
Mar 15 2023	BUY Grant, award, or other acquisition	-	16,419 Added 24.35%	51,023 Common Stock
Feb 25 2023	SELL Payment of exercise price or tax liability	$47,388 $18.54 p/Share	2,556 Reduced 6.88%	34,604 Common Stock
Mar 22 2022	BUY Grant, award, or other acquisition	-	9,754 Added 20.79%	37,160 Common Stock
Feb 25 2022	SELL Payment of exercise price or tax liability	$64,046 $24.69 p/Share	2,594 Reduced 8.65%	27,406 Common Stock
Feb 18 2021	BUY Grant, award, or other acquisition	-	30,000 Added 50.0%	30,000 Common Stock

Margaret Ancona

EVP, Strategy & Transformation

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells MYGN shares.

Notify only if

Value

Insider Trading

Get notified when an Myriad Genetics Inc insider buys or sells MYGN shares.

Notify only if

Operation

Value

Type

News

Receive news related to MYRIAD GENETICS INC

Track Activities on MYGN

Account